Recombinant Human Anti-HIV-1 gp120 Antibody (45-46M2) (CAT#: PABZ-169)

Recombinant Human Antibody (45-46M2) is capable of binding to HIV-1 gp120, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 gp120 mAb and CH1-3 region of human IgG and a light chain (LC) encoding VL from anti-HIV-1 gp120 proteins mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. Antibodie 45-46m2 targeting only two epitopes, can control viremia in vivo; thus, this combination of bNAbs was able to suppress both the parental viral YU-2 viral strain and N/DNGG consensus-based escape mutants.

Specific Inquiry Online Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 Comparison of neutralization potencies of 45-46m bNAb mutants.

Figure 1 Comparison of neutralization potencies of 45-46m bNAb mutants.

(A) Summary of 45-46m mutants. (B) Coverage curves showing the cumulative frequency of IC₅₀ values up to the concentration shown on the x axis (plot of the percent of viral strains [y axis] from a panel of 118 strains that were neutralized at a given IC₅₀ cutoff [x axis]). A vertical line at 0.1 µg/ml designates a theoretical desired potency for a therapeutic reagent. (C) Table showing IC₅₀ values (µg/ml) for NIH45-46, NIH45-46G54W, 45-46m2, and 45-46m7 against 28 strains that are resistant to or poorly neutralized by NIH45-46. Strains marked in blue have an altered N/DNGG motif. IC₅₀s were derived from curves generated from data points obtained in duplicate or triplicate.

Diskin, R., Klein, F., Horwitz, J. A., Halper-Stromberg, A., Sather, D. N., Marcovecchio, P. M., ... & Stamatatos, L. (2013). Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies. Journal of Experimental Medicine, 210(6), 1235-1249.

Figure 2 Neutralization of highly resistant viral clones from patient VC10042.

Figure 2 Neutralization of highly resistant viral clones from patient VC10042.

(A) Neutralization curves for NIH45-46G54W, 45-46m2, and 45-46m7 against 10 viral clones from patient VC10042 that were isolated 19 yr (first three panels) or 22 yr (remaining panels) after infection. (B) Scatter plot comparing IC₅₀ values (µg/ml) for VRC01, NIH45-46G54W, 45-46m2, and 45-46m7 against viral clones from patient VC10042. Despite their breadth, 45-46m2 and 45-46m7 did not neutralize SIV strains (SIVmac251 and SIVsmE660; not depicted). (C) IC₅₀ values (µg/ml) for NIH45-46G54W, 45-46m2, and 45-46m7 against viral clones from patient VC10042. The reported IC₅₀ values represent the mean of two independent experiments, each with two replicates. Significance of statistical differences: * (VRC01 and 45-46m2), P < 0.0001; ** (NIH45-46G54W and 45-46m2), P = 0.0033; *** (45-46m2 and 45-46m7), P = 0.0274. Error bars represent standard deviation from the mean.

Diskin, R., Klein, F., Horwitz, J. A., Halper-Stromberg, A., Sather, D. N., Marcovecchio, P. M., ... & Stamatatos, L. (2013). Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies. Journal of Experimental Medicine, 210(6), 1235-1249.

Figure 3 SPR comparisons of the binding of gp120 to NIH45-46, NIH4546G54W, and 45-46m2 Fabs.

Figure 3 SPR comparisons of the binding of gp120 to NIH45-46, NIH4546G54W, and 45-46m2 Fabs.

(A) Sensograms (orange curves) were recorded for the interactions of injected 93TH057 gp120 produced in insect (Hi5) and mammalian (HEK293) cells over immobilized Fabs derived from the indicated antibodies in a twofold dilution series ranging from 500 to 31 nM. Kinetic constants (kₐ, kd) were derived from globally fitting the association and dissociation phases using a 1:1 binding model (black curves) and affinities were calculated as KD = kd/kₐ. Residual plots (blue) within each sensogram describe the fit of the model to the data. Each binding experiment was conducted twice; once using gp120 produced in insect cells and once using gp120 produced in mammalian cells. (B) SPR measurements of 500 nM injected 93TH057 gp120 over the indicated immobilized Fabs. Each curve was normalized to its Rmax. The gray and white shaded areas designate the association and dissociation phases, respectively.

Diskin, R., Klein, F., Horwitz, J. A., Halper-Stromberg, A., Sather, D. N., Marcovecchio, P. M., ... & Stamatatos, L. (2013). Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies. Journal of Experimental Medicine, 210(6), 1235-1249.

Figure 4 Levels of neutralizing mAbs in the plasma of passively transferred macaques.

Figure 4 Levels of neutralizing mAbs in the plasma of passively transferred macaques.

The concentrations of the indicated mAbs in plasma at various times after administration were determined by ELISA using recombinant HIV-1 gp120. Plasma antibody levels were measured in the animals described in Table 2. Means and SDs are shown.

Shingai, M., Donau, O. K., Plishka, R. J., Buckler-White, A., Mascola, J. R., Nabel, G. J., ... & Diskin, R. (2014). Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. Journal of Experimental Medicine, 211(10), 2061-2074.


Specifications

  • Immunogen
  • HIV-1 gp160; envelope glycoprotein
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG
  • Specificity
  • Tested positive against native HIV-1 gp120
  • Species Reactivity
  • HIV-1
  • Clone
  • 45-46M2
  • Applications
  • ELISA Assay-Dependent
    Neut Assay-Dependent

Product Property

  • Purity
  • >95% by SDS-PAGE and HPLC analysis
  • Storage
  • Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Applications

  • Application Notes
  • The antibody 45-46M2 has been reported in applications of ELISA, Neut. It's recommended that the optimal antibody concentration, dilution, incubition time etc. are best to be carefully titrated in specific assays.

Target

  • Alternative Names
  • ENV; gp160; envelope glycoprotein; Envelope surface glycoprotein gp160, precursor; hypothetical protein; Envelope surface glycoprotein gp120; Envelope transmembrane domain;

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 45-46M2"

See other products for "env"

Select a product category from the dropdown menu below to view related products.
Please select product type
Immunotoxin scFv Fragment Antibody Single-domain Antibody Recombinant Antibody Fab Fragment Antibody MHC Tetramer for Virology
CAT Product Name Application Type
AGTO-L012R anti-env immunotoxin 907 (IgG)-RTA Cytotoxicity assay, Functional assay

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for PABZ-169. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare